Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 2/20 | 0.71 |
| ▸ | PTGS2 | P35354 | 14/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.58 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.58 |
| ▸ | TTR | P02766 | 1/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.58 |
| ▸ | FABP2 | P12104 | 1/20 | 0.58 |
| ▸ | RXRA | P19793 | 1/20 | 0.58 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.58 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.58 |
| ▸ | PDE4A | P27815 | 1/20 | 0.58 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.58 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.58 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.58 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29481381 | 0.97 | METTL3 (0.76) | METTL3PTGS2MEN1MAPK1KMT2A | |
| SCHEMBL4434232 | 0.97 | METTL3 (0.76) | METTL3PTGS2MEN1MAPK1KMT2A | |
| Hydrochloric Acid SCHEMBL2582024 | 0.96 | METTL3 (0.74) | METTL3PTGS2MEN1MAPK1KMT2A | |
| Meclofenamic Acid SCHEMBL28346421 | 0.89 | PTGS2 (0.67) | METTL3PTGS2MEN1MAPK1KMT2A | |
| Acetic Acid SCHEMBL28298024 | 0.87 | CLCN2 (0.53) | METTL3PTGS2MEN1MAPK1KMT2A | |
| SCHEMBL23386249 | 0.84 | METTL3 (1.00) | METTL3PTGS2MEN1MAPK1KMT2A | |
| Acetic Acid SCHEMBL28343515 | 0.83 | PTGS2 (0.72) | METTL3PTGS2MEN1MAPK1KMT2A | |
| Terofenamate SCHEMBL16760954 | 0.82 | METTL3 (0.79) | METTL3PTGS2MEN1MAPK1KMT2A | |
| Terofenamate SCHEMBL21834998 | 0.82 | METTL3 (0.78) | METTL3PTGS2MEN1MAPK1KMT2A | |
| SCHEMBL10529901 | 0.81 | METTL3 (0.80) | METTL3PTGS2MEN1MAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112521305-A | Novel high-penetration medicine for treating Parkinson's disease and medicine composition thereof | 苏州泰飞尔医药有限公司 | 2021-03-19 | — | — | CN | claimed |
| CN-104706630-B | Positively charged water-soluble prodrugs of aryl anthranilic acids with fast skin penetration rates | 于崇曦 | 2020-01-10 | — | — | CN | claimed |
| US-9718766-B2 | High penetration drugs and their compositions thereof for treatment of parkinson diseases | TECHFIELDS PHARMA CO., LTD. (CN) | 2017-08-01 | — | — | US | claimed |
| US-20160002157-A1 | NOVEL HIGH PENETRATION DRUGS AND THEIR COMPOSITIONS THEREOF FOR TREATMENT OF PARKINSON DISEASES | PREMIER RESEARCH INTERNATIONAL, LLC | 2016-01-07 | — | — | US | claimed |
| US-11685739-B2 | High penetration drugs and their compositions thereof for treatment of Parkinson diseases | TECHFIELDS PHARMA CO., LTD. (CN) | 2023-06-27 | — | — | US | disclosed |
| CN-112521305-B | Novel high penetration drug for treating Parkinson disease and pharmaceutical composition thereof | 苏州泰飞尔医药有限公司 | 2023-04-25 | — | — | CN | disclosed |
| CN-105820107-B | Prodrug of non-steroidal anti-inflammatory drug with rapid skin and biological membrane penetration speed and novel medical application thereof | 泰飞尔公司 | 2022-09-09 | — | — | CN | disclosed |
| US-11084813-B2 | High penetration drugs and their compositions thereof for treatment of Parkinson diseases | TECHFIELDS PHARMA CO., LTD. (CN) | 2021-08-10 | — | — | US | disclosed |
| CN-112521305-A | Novel high-penetration medicine for treating Parkinson's disease and medicine composition thereof | 苏州泰飞尔医药有限公司 | 2021-03-19 | — | — | CN | disclosed |
| CN-105143174-B | Novel high-penetration medicine for treating Parkinson's disease and medicine composition thereof | 苏州泰飞尔医药有限公司 | 2021-01-12 | — | — | CN | disclosed |
| CN-104706630-B | Positively charged water-soluble prodrugs of aryl anthranilic acids with fast skin penetration rates | 于崇曦 | 2020-01-10 | — | — | CN | disclosed |
| US-20170334908-A1 | NOVEL HIGH PENETRATION DRUGS AND THEIR COMPOSITIONS THEREOF FOR TREATMENT OF PARKINSON DISEASES | PREMIER RESEARCH INTERNATIONAL, LLC | 2017-11-23 | — | — | US | disclosed |
| US-9718766-B2 | High penetration drugs and their compositions thereof for treatment of parkinson diseases | TECHFIELDS PHARMA CO., LTD. (CN) | 2017-08-01 | — | — | US | disclosed |
| EP-2994453-A1 | NOVEL HIGH PENETRATION DRUGS AND THEIR COMPOSITIONS THEREOF FOR TREATMENT OF PARKINSON DISEASES | Techfields Pharma Co., Ltd. (CN) | 2016-03-16 | — | — | EP | disclosed |
| US-20160002157-A1 | NOVEL HIGH PENETRATION DRUGS AND THEIR COMPOSITIONS THEREOF FOR TREATMENT OF PARKINSON DISEASES | PREMIER RESEARCH INTERNATIONAL, LLC | 2016-01-07 | — | — | US | disclosed |
| WO-2014139161-A1 | NOVEL HIGH PENETRATION DRUGS AND THEIR COMPOSITIONS THEREOF FOR TREATMENT OF PARKINSON DISEASES | TECHFIELDS PHARMA CO., LTD. (CN) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334908-A1 | NOVEL HIGH PENETRATION DRUGS AND THEIR COMPOSITIONS THEREOF FOR TREATMENT OF PARKINSON DISEASES | ABCB1, PARK7, SLC5A7 | METTL3 4591/4885PTGS2 366/4885MEN1 3256/4885 |
| US-11084813-B2 | High penetration drugs and their compositions thereof for treatment of Parkinson diseases | ABCB1, PARK7, ABCG2 | METTL3 4214/4885PTGS2 348/4885MEN1 2860/4885 |
| US-20160002157-A1 | NOVEL HIGH PENETRATION DRUGS AND THEIR COMPOSITIONS THEREOF FOR TREATMENT OF PARKINSON DISEASES | ABCB1, PARK7, SLC5A7 | METTL3 4591/4885PTGS2 366/4885MEN1 3256/4885 |
| US-11685739-B2 | High penetration drugs and their compositions thereof for treatment of Parkinson diseases | ABCB1, PARK7, ABCG2 | METTL3 4214/4885PTGS2 348/4885MEN1 2860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.